Goldman Sachs’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,030,039
| Closed | -$28.4M | – | 6728 |
|
|
2021
Q2 | $28.4M | Sell |
1,030,039
-562,472
| -35% | -$11.1M | 0.01% | 1744 |
|
|
2021
Q1 | $26.3M | Buy |
1,592,511
+610,590
| +62% | +$13.9M | 0.01% | 1708 |
|
|
2020
Q4 | $18.1M | Sell |
981,921
-838,406
| -46% | -$15M | ﹤0.01% | 1948 |
|
|
2020
Q3 | $24.8M | Buy |
1,820,327
+1,533,312
| +534% | +$23.6M | 0.01% | 1562 |
|
|
2020
Q2 | $5.14M | Buy |
287,015
+232,984
| +431% | +$3.51M | ﹤0.01% | 2789 |
|
|
2020
Q1 | $539K | Sell |
54,031
-3,290
| -6% | -$27K | ﹤0.01% | 4171 |
|
|
2019
Q4 | $466K | Buy |
57,321
+30,185
| +111% | +$279K | ﹤0.01% | 4546 |
|
|
2019
Q3 | $269K | Sell |
27,136
-40,196
| -60% | -$380K | ﹤0.01% | 4725 |
|
|
2019
Q2 | $850K | Buy |
67,332
+41,897
| +165% | +$442K | ﹤0.01% | 4095 |
|
|
2019
Q1 | $259K | Buy |
25,435
+8,561
| +51% | +$65.6K | ﹤0.01% | 4691 |
|
|
2018
Q4 | $127K | Buy |
16,874
+173
| +1% | +$1.27K | ﹤0.01% | 4954 |
|
|
2018
Q3 | $167K | Sell |
16,701
-76,799
| -82% | -$894K | ﹤0.01% | 4971 |
|
|
2018
Q2 | $1.18M | Buy |
+93,500
| New | +$1.13M | ﹤0.01% | 3968 |
|
Goldman Sachs's TBIO Position: Q3 2021 in Review
Goldman Sachs sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 1,030,039 shares — an estimated $28.4M sold.
Goldman Sachs first reported a position in TBIO in Q2 2018 and held it in 13 quarters. The position peaked at $28.4M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- Goldman Sachs reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- Goldman Sachs sold 1,030,039 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $28.4M.
- Goldman Sachs first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
- Goldman Sachs's Translate Bio, Inc. Common Stock position peaked at $28.4M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.